{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:04:49Z","timestamp":1793138689912,"version":"4.5.0"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Thyroid eye disease (TED) is a disfiguring autoimmune disease characterized by changes in the orbital tissues and is caused by abnormal thyroid function or thyroid-related antibodies. It is the ocular manifestation of Graves\u2019 disease. The expression of thyroid-stimulating hormone receptor (TSHR) and the insulin-like growth factor-1 receptor (IGF-1 R) on the cell membrane of orbital fibroblasts (OFs) is responsible for TED pathology. Excessive inflammation is caused when these receptors in the orbit are stimulated by autoantibodies. CD34<jats:sup>+<\/jats:sup> fibrocytes, found in the peripheral blood and orbital tissues of patients with TED, express immune checkpoints (ICs) like MHC II, B7, and PD-L1, indicating their potential role in presenting antigens and regulating the immune response in TED pathogenesis. Immune checkpoint inhibitors (ICIs) have significantly transformed cancer treatment. However, it can also lead to the occurrence of TED in some instances, suggesting the abnormality of ICs in TED. This review will examine the overall pathogenic mechanism linked to the immune cells of TED and then discuss the latest research findings on the immunomodulatory role of ICs in the development and pathogenesis of TED. This will offer fresh perspectives on the study of pathogenesis and the identification of potential therapeutic targets.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1392956","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T04:26:15Z","timestamp":1715833575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Immune checkpoints: new insights into the pathogenesis of thyroid eye disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Xingyi","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruili","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5694\/mja16.00586","article-title":"Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)","volume":"205","author":"Bourke","year":"2016","journal-title":"Med J Aust"},{"key":"B2","doi-asserted-by":"publisher","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_114","article-title":"LAG-3 in cancer immunotherapy","volume":"344","author":"Goldberg","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa176","article-title":"Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response","volume":"22","author":"Hu","year":"2021","journal-title":"Brief Bioinform"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: A systematic review","volume":"12","author":"Yu","year":"2020","journal-title":"Eye Brain"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701951","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthalmic Inflammation Infect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3390\/jcm8111842","article-title":"Investigation of the correlation between graves\u2019 Ophthalmopathy and CTLA4 gene polymorphism","volume":"8","author":"Chen","year":"2019","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcad176","article-title":"Euthyroid graves\u2019 ophthalmopathy","volume":"116","author":"Schattner","year":"2023","journal-title":"QJM"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00417-023-05998-2","article-title":"Clinical phenotypes of euthyroid, hyperthyroid, and hypothyroid thyroid-associated ophthalmopathy","volume":"261","author":"Yang","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1097\/IOP.0000000000000509","article-title":"Inflammatory orbitopathy associated with ipilimumab","volume":"33","author":"Sheldon","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001161","article-title":"Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00442","article-title":"Rapid development of graves\u2019 Ophthalmopathy after treatment with ipilimumab and recurrence with pembrolizumab in a patient with previously treated graves\u2019 Disease","volume":"14","author":"Rhea","year":"2018","journal-title":"J Oncol Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2018.01.006","article-title":"A case of Graves\u2019 ophthalmopathy associated with pembrolizumab (Keytruda) therapy","volume":"22","author":"Park","year":"2018","journal-title":"J AAPOS"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002467","article-title":"Thyroid eye disease: epidemiology, natural history, and risk factors","volume":"39","author":"Bartalena","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad501","article-title":"Increased risk of thyroid eye disease following covid-19 vaccination","volume":"109","author":"Muller","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648732","article-title":"Mechanisms that underly T cell immunity in graves\u2019 Orbitopathy","volume":"12","author":"Fang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20199","article-title":"IL-17A promotes RANTES expression, but not IL-16, in orbital fibroblasts via CD40-CD40L combination in thyroid-associated ophthalmopathy","volume":"57","author":"Fang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2018.09.05","article-title":"Frequency of IL-10-producing regulatory B cells associated with disease activity in thyroid-associated orbitopathy","volume":"11","author":"Ding","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/1566524018666180705105753","article-title":"Decreased expression of TIM-3 on th17 cells associated with ophthalmopathy in patients with graves\u2019 Disease","volume":"18","author":"Zhao","year":"2018","journal-title":"Curr Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.849480","article-title":"PD-L1 inhibits T cell-induced cytokines and hyaluronan expression via the CD40-CD40L pathway in orbital fibroblasts from patients with thyroid associated ophthalmopathy","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100699","DOI":"10.1016\/j.xcrm.2022.100699","article-title":"Single-cell RNA sequencing depicts the local cell landscape in thyroid-associated ophthalmopathy","volume":"3","author":"Li","year":"2022","journal-title":"Cell Rep Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.0806","article-title":"Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy","volume":"136","author":"Rotondo Dottore","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0254","article-title":"M1-like macrophages modulate fibrosis and inflammation of orbital fibroblasts in graves\u2019 Orbitopathy: potential relevance to soluble interleukin-6 receptor","volume":"33","author":"Lu","year":"2023","journal-title":"Thyroid"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2007.0407","article-title":"Immune mechanisms in thyroid eye disease","volume":"18","author":"Lehmann","year":"2008","journal-title":"Thyroid"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114244118","article-title":"Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy","volume":"118","author":"Fernando","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B37","article-title":"Clinical lectures delivered at the Meath Hospital during the session 1834\u20131835","volume":"7","author":"Graves","year":"1835","journal-title":"Lecture XII. Lond Med Surg J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the European Thyroid Association","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0712","article-title":"Intravenous glucocorticoid therapy for Graves\u2019 ophthalmopathy and acute liver damage: an epidemiological study","volume":"172","author":"Sisti","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 receptor tocilizumab in refractory graves\u2019 Orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"Sanchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/jcm10040706","article-title":"Steroid-resistant graves\u2019 Orbitopathy treated with tocilizumab in real-world clinical practice: A 9-year single-center experience","volume":"10","author":"Perez-Moreiras","year":"2021","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0269","article-title":"Efficacy profile and safety of very low-dose rituximab in patients with graves\u2019 Orbitopathy","volume":"31","author":"Vannucchi","year":"2021","journal-title":"Thyroid"},{"key":"B46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ando.2020.01.003","article-title":"Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population","volume":"81","author":"Ceballos-Macias Jose","year":"2020","journal-title":"Ann Endocrinol (Paris)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.7.2557","article-title":"Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor","volume":"84","author":"Valyasevi","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1210\/clinem\/dgac045","article-title":"It takes two to tango: IGF-I and TSH receptors in thyroid eye disease","volume":"107","author":"Girnita","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0254","article-title":"Forkhead transcription factor FOXO1 is regulated by both a stimulatory thyrotropin receptor antibody and insulin-like growth factor-1 in orbital fibroblasts from patients with graves\u2019 Ophthalmopathy","volume":"25","author":"Kumar","year":"2015","journal-title":"Thyroid"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2932","article-title":"Reversal of pathological features of graves\u2019 Orbitopathy by activation of forkhead transcription factors, FOXOs","volume":"101","author":"Zhang","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B53","doi-asserted-by":"publisher","first-page":"151902","DOI":"10.1016\/j.imbio.2019.151902","article-title":"Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy","volume":"225","author":"Paik","year":"2020","journal-title":"Immunobiology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01349","article-title":"Regulation of orbital fibrosis and adipogenesis by pathogenic th17 cells in graves orbitopathy","volume":"102","author":"Fang","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/IOP.0000000000002509","article-title":"Fibrocyte participation in thyroid-associated ophthalmopathy suggests new approaches to therapy","volume":"39","author":"Smith","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2328","article-title":"Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1","volume":"50","author":"Hwang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0173","article-title":"A multicenter, single-blind, case-control, immunohistochemical study of orbital tissue in thyroid eye disease","volume":"32","author":"Hai","year":"2022","journal-title":"Thyroid"},{"key":"B58","doi-asserted-by":"publisher","first-page":"340934","DOI":"10.1155\/2015\/340934","article-title":"Disturbances of modulating molecules (FOXP3, CTLA-4\/CD28\/B7, and CD40\/CD40L) mRNA expressions in the orbital tissue from patients with severe graves\u2019 ophthalmopathy","volume":"2015","author":"Pawlowski","year":"2015","journal-title":"Mediators Inflammation"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.691781","article-title":"Precision medicine in graves\u2019 Disease: CD40 gene variants predict clinical response to an anti-CD40 monoclonal antibody","volume":"12","author":"Faustino","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.060434","article-title":"Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes","volume":"169","author":"Feldon","year":"2006","journal-title":"Am J Pathol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020987","article-title":"Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use","volume":"88","author":"Starkey","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"895901","DOI":"10.1155\/2008\/895901","article-title":"Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation","volume":"2008","author":"Lehmann","year":"2008","journal-title":"PPAR Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1614","article-title":"Increased generation of fibrocytes in thyroid-associated ophthalmopathy","volume":"95","author":"Douglas","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0412-4081.2017.06.017","article-title":"[Bone marrow-derived fibrocytes and thyroid-associated opthalmopathy]","volume":"53","author":"Wu","year":"2017","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02865-0","article-title":"Peripheral blood mononuclear cells - Can they provide a clue to the pathogenesis of Graves\u2019 Orbitopathy","volume":"75","author":"Basak","year":"2022","journal-title":"Endocrine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800259","article-title":"Slit2 modulates the inflammatory phenotype of orbit-infiltrating fibrocytes in graves\u2019 Disease","volume":"200","author":"Fernando","year":"2018","journal-title":"J Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1998.274.3.C707","article-title":"Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production","volume":"274","author":"Sempowski","year":"1998","journal-title":"Am J Physiol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.45.29615","article-title":"Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy","volume":"273","author":"Cao","year":"1998","journal-title":"J Biol Chem"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-3789","article-title":"The expression of intercellular adhesion molecule-1 induced by CD40-CD40L ligand signaling in orbital fibroblasts in patients with Graves\u2019 ophthalmopathy","volume":"51","author":"Zhao","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2902-1","article-title":"CD40 ligand induces expression of vascular cell adhesion molecule 1 and E-selectin in orbital fibroblasts from patients with Graves\u2019 orbitopathy","volume":"253","author":"Wang","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.64.11.13","article-title":"The role of adipsin, complement factor D, in the pathogenesis of graves\u2019 Orbitopathy","volume":"64","author":"Byeon","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25466","article-title":"CD40 enhances sphingolipids in orbital fibroblasts: potential role of sphingosine-1-phosphate in inflammatory T-cell migration in graves\u2019 Orbitopathy","volume":"59","author":"Pl\u00f6hn","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9861","article-title":"Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-\u03baB","volume":"53","author":"Gillespie","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B76","first-page":"26","article-title":"Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis)","volume":"112","author":"Douglas","year":"2014","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0243","article-title":"Thyrotropin and CD40L stimulate interleukin-12 expression in fibrocytes: implications for pathogenesis of thyroid-associated ophthalmopathy","volume":"26","author":"Wu","year":"2016","journal-title":"Thyroid"},{"key":"B78","first-page":"10","article-title":"Association between the CD40 rs1883832 polymorphism and Graves\u2019 disease risk: a meta-analysis","volume":"18","author":"Wang","year":"2019","journal-title":"Excli J"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011520","article-title":"CD40: novel association with Crohn\u2019s disease and replication in multiple sclerosis susceptibility","volume":"5","author":"Blanco-Kelly","year":"2010","journal-title":"PloS One"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0605","article-title":"Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves\u2019 ophthalmopathy","volume":"46","author":"Feldon","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.8.8768872","article-title":"Orbital tissue-derived T lymphocytes from patients with Graves\u2019 ophthalmopathy recognize autologous orbital antigens","volume":"81","author":"Otto","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.imlet.2015.03.010","article-title":"Characterization and clinical relevance of circulating CD4+CD28- T cells in Graves\u2019 disease","volume":"165","author":"Wang","year":"2015","journal-title":"Immunol Lett"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.2.1018","article-title":"Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients","volume":"161","author":"Schirmer","year":"1998","journal-title":"J Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12967-023-04217-0","article-title":"RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: immune checkpoint inhibitors","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2087525","DOI":"10.1155\/2016\/2087525","article-title":"Treatment of ipilimumab induced graves\u2019 Disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1159\/000464285","article-title":"Tremelimumab-induced graves hyperthyroidism","volume":"6","author":"Gan","year":"2017","journal-title":"Eur Thyroid J"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01465-8","article-title":"Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy","volume":"354","author":"Vaidya","year":"1999","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0007","article-title":"Genetic profiling in Graves\u2019 disease: further evidence for lack of a distinct genetic contribution to Graves\u2019 ophthalmopathy","volume":"22","author":"Yin","year":"2012","journal-title":"Thyroid"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.2006.B0887","article-title":"Association of Graves\u2019 disease and Graves\u2019 ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene","volume":"7","author":"Zhang","year":"2006","journal-title":"J Zhejiang Univ Sci B"},{"key":"B95","doi-asserted-by":"publisher","first-page":"537969","DOI":"10.1155\/2014\/537969","article-title":"Associations of CTLA4 gene polymorphisms with graves\u2019 Ophthalmopathy: A meta-analysis","volume":"2014","author":"Du","year":"2014","journal-title":"Int J Genomics"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M206894200","article-title":"A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele","volume":"277","author":"Anjos","year":"2002","journal-title":"J Biol Chem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-313X.2006.00614.x","article-title":"The common -318C\/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves\u2019 patients","volume":"33","author":"Han","year":"2006","journal-title":"Int J Immunogenet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.mce.2017.03.006","article-title":"Frequencies of PD-1- positive T CD3+CD4+, T CD3+CD8+ and B CD19+ lymphocytes in female patients with Graves\u2019 disease and healthy controls- preliminary study","volume":"448","author":"Pyzik","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2174\/138920211798120844","article-title":"Graves\u2019 ophthalmopathy: a review of immunogenetics","volume":"12","author":"Khalilzadeh","year":"2011","journal-title":"Curr Genomics"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123938","article-title":"Graves\u2019 disease is associated with a defective expression of the immune regulatory molecule galectin-9 in antigen-presenting dendritic cells","volume":"10","author":"Leskela","year":"2015","journal-title":"PloS One"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.07.021","article-title":"The association between polymorphisms of B7 molecules (CD80 and CD86) and Graves\u2019 ophthalmopathy in a Taiwanese population","volume":"118","author":"Liao","year":"2011","journal-title":"Ophthalmology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0282-1","article-title":"Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves\u2019 orbitopathy: a case series","volume":"33","author":"Roos","year":"2019","journal-title":"Eye (Lond)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1501","article-title":"Graves\u2019 disease after treatment with alemtuzumab for multiple sclerosis","volume":"14","author":"Tsourdi","year":"2015","journal-title":"Hormones (Athens)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000310","article-title":"Ocular findings in alemtuzumab (Campath-1H)-induced thyroid eye disease","volume":"32","author":"Trinh","year":"2016","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B108","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13643-021-01782-7","article-title":"Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature","volume":"10","author":"Mu\u00f1oz-Ortiz","year":"2021","journal-title":"Syst Rev"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4158\/EP13020.RA","article-title":"Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review","volume":"19","author":"Aranha","year":"2013","journal-title":"Endocr Pract"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37878","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Invest"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111521","article-title":"Tissue-resident memory T cells in renal autoimmune diseases","volume":"14","author":"Ginsberg","year":"2023","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nature11132","article-title":"PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells","volume":"486","author":"Cipolletta","year":"2012","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw0638","article-title":"Apoptosis of hematopoietic progenitor-derived adipose tissue-resident macrophages contributes to insulin resistance after myocardial infarction","volume":"12","author":"Vasamsetti","year":"2020","journal-title":"Sci Transl Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0362","article-title":"Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T cells and th1\/tc1 cytokines","volume":"10","author":"Reschke","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12964-022-00849-9","article-title":"The activation of PPARgamma enhances Treg responses through up-regulating CD36\/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of TbetaRII\/IL-2Ralpha","volume":"20","author":"Miao","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B116","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.10.018","article-title":"Teprotumumab-related adverse events in thyroid eye disease: A multicenter study","volume":"131","author":"Shah","year":"2024","journal-title":"Ophthalmology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1392956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T04:26:20Z","timestamp":1715833580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1392956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":117,"alternative-id":["10.3389\/fimmu.2024.1392956"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1392956","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"article-number":"1392956"}}